Amunix Pharmaceuticals
Biotechnology, 2 Tower Place, South San Francisco, California, 94080, United States, 11-50 Employees
Phone Number: 65********
Who is AMUNIX PHARMACEUTICALS
Amunix is an immuno-oncology company leveraging our proprietary, clinically validated Pro-XTEN technology platform to discover and develop transformative T cell engagers (TCEs) and cytoki...
Read More
-
Headquarters: 2 Tower Place, South San Francisco, California, 94080, United States
-
Date Founded: 2006
-
Employees: 11-50
-
Revenue: $50 Million to $100 Million
-
Active Tech Stack: See technologies
-
CEO:
Martina Manack
Email
Phone
Industry: Biotechnology
SIC Code: 2836
|
NAICS Code: 541714 |
Show More
Does something look wrong? Fix it. | View contact records from AMUNIX PHARMACEUTICALS
Amunix Pharmaceuticals Org Chart and Mapping
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Amunix Pharmaceuticals
Answer: Amunix Pharmaceuticals's headquarters are located at 2 Tower Place, South San Francisco, California, 94080, United States
Answer: Amunix Pharmaceuticals's phone number is 65********
Answer: Amunix Pharmaceuticals's official website is https://amunix.com
Answer: Amunix Pharmaceuticals's revenue is $50 Million to $100 Million
Answer: Amunix Pharmaceuticals's SIC: 2836
Answer: Amunix Pharmaceuticals's NAICS: 541714
Answer: Amunix Pharmaceuticals has 11-50 employees
Answer: Amunix Pharmaceuticals is in Biotechnology
Answer: Amunix Pharmaceuticals contact info: Phone number: 65******** Website: https://amunix.com
Answer: Amunix is an immuno-oncology company leveraging our proprietary, clinically validated Pro-XTEN technology platform to discover and develop transformative T cell engagers (TCEs) and cytokine therapies for patients with cancer. We aim to expand the therapeutic index of TCEs and cytokines, which have demonstrated anti-tumor clinical activity, but have not realized their potential due to dose-limiting on-target, off-tumor toxicity. We address this challenge by using our universal, protease-releasable masking technology (Pro-XTEN), to create next generation, conditionally active TCEs (XPATs) and cytokines (XPACs), that are preferentially activated in tumors as compared to healthy tissues. Experience and culture matter. At Amunix, we challenge ourselves and our colleagues, and bring a critical eye and rigor to everything we do. Biology is complex and hard to predict, but with deep experience, diversity of thinking, and scientific rigor, we believe we maximize our chance of making a real difference for cancer patients.
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
CEO at Amunix Pharmaceuticals
Sign in to CIENCE GO Data to uncover contact details
Free credits every month